Get started
Alivus Life Sciences LtdAlivus Life Sciences LtdAlivus Life Sciences Ltd

Alivus Life Sciences Ltd

No trades
No trades
OverviewFinancialsDocumentsNewsCommunityTechnicalsForecastsSeasonalsETFs
Full chart
Full chart

Compare with Alivus Life Sciences Ltd



Key stats


Market capitalization
‪168.23 B‬ INR
Dividend yield (indicated)
0.37%
Price to earnings Ratio (TTM)
27.9
Basic EPS (TTM)
49.1 INR
Net income (FY)
‪5.64 B‬ INR
Revenue (FY)
‪25.36 B‬ INR
Shares float
‪30.88 M‬
Beta (1Y)
0.56

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Employees


Employees (FY)
‪3.95 K‬
Change (1Y)
+14+0.36%
Revenue / Employee (1Y)
‪6.42 M‬ INR
Net income / Employee (1Y)
‪1.43 M‬ INR

Company info


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Yasir Rawjee
Website
glenmarklifesciences.com
Headquarters
Mumbai
Founded
2011
IPO date
Aug 6, 2021
ISIN
INE03Q201024
FIGI
BBG011WT9KP6
Identifiers
ISIN INE03Q201024
CFI code
ESVUFN
Alivus Life Sciences Ltd. engages in the provision of development and manufacture of non-commoditized active pharmaceutical ingredients. It operates through the Within India and Outside India geographical segments. Its products focus on chronic therapeutic areas, including cardiovascular disease, central nervous system disease, pain management, and diabetes. The company was founded on June 23, 2011 and is headquartered in Mumbai, India.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
Neutral
Neutral

Analyst rating


An aggregate view of professional's ratings.
Neutral
Neutral
Neutral

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs holding the stock


SMIN
Ishares MSCI India Small Cap ETF
Weight0.12%
Market value‪814.31 K‬
EPI
WisdomTree India Earnings Fund
Weight0.02%
Market value‪319.79 K‬
EWX
State Street SPDR S&P Emerging Markets Small Cap ETF
Weight0.03%
Market value‪225.93 K‬
MOHEALTH
Motilal Oswal S&P BSE Healthcare ETF
Weight0.27%
Market value‪12.28 K‬

Explore more ETFs 

Frequently asked questions


The current price of ALIVUS is 1,326.3 INR — it has decreased by −2.41% in the past 24 hours. Watch Alivus Life Sciences Ltd stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NSE exchange Alivus Life Sciences Ltd stocks are traded under the ticker ALIVUS.
ALIVUS stock has fallen by −2.75% compared to the previous week, the month change is a −3.85% fall, over the last year Alivus Life Sciences Ltd has showed a 45.40% increase.
We've gathered analysts' opinions on Alivus Life Sciences Ltd future price: according to them, ALIVUS price has a max estimate of 1,624.00 INR and a min estimate of 1,375.00 INR. Watch ALIVUS chart and read a more detailed Alivus Life Sciences Ltd stock forecast: see what analysts think of Alivus Life Sciences Ltd and suggest that you do with its stocks.
ALIVUS reached its all-time high on Aug 31, 2026 with the price of 1,493.8 INR, and its all-time low was 370.0 INR and was reached on Sep 28, 2022. View more price dynamics on ALIVUS chart.
See other stocks reaching their highest and lowest prices.
ALIVUS stock is 4.04% volatile and has beta coefficient of 0.56. Track Alivus Life Sciences Ltd stock price on the chart and check out the list of the most volatile stocks — is Alivus Life Sciences Ltd there?
Today Alivus Life Sciences Ltd has the market capitalization of ‪164.24 B‬, it has increased by 0.31% over the last week.
Yes, you can track Alivus Life Sciences Ltd financials in yearly and quarterly reports right on TradingView.
Alivus Life Sciences Ltd is going to release the next earnings report on Nov 5, 2026. Keep track of upcoming events with our Earnings Calendar.
ALIVUS earnings for the last quarter are 13.00 INR per share, whereas the estimation was 12.10 INR resulting in a 7.44% surprise. The estimated earnings for the next quarter are 12.50 INR per share. See more details about Alivus Life Sciences Ltd earnings.
Alivus Life Sciences Ltd revenue for the last quarter amounts to ‪6.40 B‬ INR, despite the estimated figure of ‪6.80 B‬ INR. In the next quarter, revenue is expected to reach ‪6.42 B‬ INR.
ALIVUS net income for the last quarter is ‪1.60 B‬ INR, while the quarter before that showed ‪1.63 B‬ INR of net income which accounts for 0.00% change. Track more Alivus Life Sciences Ltd financial stats to get the full picture.
Yes, ALIVUS dividends are paid annually. The last dividend per share was 5.00 INR. As of today, Dividend Yield (TTM)% is 0.37%. Tracking Alivus Life Sciences Ltd dividends might help you take more informed decisions.
Alivus Life Sciences Ltd dividend yield was 0.51% in 2025, and payout ratio reached 10.87%. The year before the numbers were 0.46% and 12.62% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Oct 9, 2026, the company has ‪3.95 K‬ employees. See our rating of the largest employees — is Alivus Life Sciences Ltd on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Alivus Life Sciences Ltd EBITDA is ‪8.37 B‬ INR, and current EBITDA margin is 31.36%. See more stats in Alivus Life Sciences Ltd financial statements.
Like other stocks, ALIVUS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Alivus Life Sciences Ltd stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Alivus Life Sciences Ltd technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Alivus Life Sciences Ltd stock shows the buy signal. See more of Alivus Life Sciences Ltd technicals for a more comprehensive analysis.